Nippon Kayaku Co., Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nippon Kayaku Co., Ltd.
Plus deals involving Debiopharm/SunRock, RefleXion/3B Pharmaceuticals, Pharmanovia/Sanofi and more.
Struggling antibiotic company will go privare under the agreement. Bayer will employ Acuitas's liquid nanoparticle technology in gene therapies developed by subsidiary Asklepios.
BioAsia 2023: CEPI's CEO, Dr Richard Hatchett, talks about viruses with pandemic potential, enhanced ‘spillover risk’ and delivering on operational excellence to get to the mission of having vaccines ready for initial authorization within 100 days of identification of a pandemic pathogen.
Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.
- Generic Drugs
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- Euro Nippon Kayaku GmbH
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.